## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.6% below STRENGTH zone (3.0-6.0%); PEG 1.44 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($455.97)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. United Therapeutics Corporation $UTHR Shares Sold by L2 Asset Management LLC**
- Source: MarketBeat | 20251208T120938 | Neutral | Relevance: 99%
-  L2 Asset Management LLC significantly reduced its stake in United Therapeutics Corporation (UTHR), selling 35.6% of its shares. This comes amidst broader insider selling activity, with executives selling a substantial number of shares in recent months. Despite this, United Therapeutics shows strong financial performance, trades near its 52-week high, and has a "Moderate Buy" consensus rating from analysts who have set an average price target of $505.

**2. Epoch Investment Partners Inc. Has $83.76 Million Holdings in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251206T050325 | Somewhat-Bullish | Relevance: 98%
- Epoch Investment Partners Inc. increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 2.0% to 291,494 shares, valued at $83.76 million. The article details other institutional investments, recent analyst rating changes with a consensus "Moderate Buy" and average price target of $505.00, and insider selling activity despite the company beating quarterly EPS estimates.

**3. Amundi Has $107.11 Million Position in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251208T080938 | Somewhat-Bullish | Relevance: 98%
-  Amundi significantly increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, now holding 362,826 shares valued at approximately $107.11 million. Despite a recent earnings beat on EPS but a revenue miss, the company holds a "Moderate Buy" consensus rating from analysts, with a target price of $505.00. Insider selling has been notable, with officers selling off a substantial amount of shares in the past 90 days, even as institutional investors own the vast majority of the stock.

**4. United Therapeutics Corporation $UTHR Shares Bought by First Trust Advisors LP**
- Source: MarketBeat | 20251207T110325 | Somewhat-Bullish | Relevance: 97%
-  First Trust Advisors LP increased its stake in United Therapeutics Corporation by 2.5% in Q2, bringing their total to 305,512 shares. Institutional investors collectively own 94.08% of the company, with significant additions from Vanguard and Invesco. Despite insider sales totaling over $264 million in the last quarter, analysts maintain a "Moderate Buy" rating with a $505 price target, as the stock trades near its 52-week high following an EPS beat.

**5. United Therapeutics Corporation $UTHR Shares Acquired by Marshall Wace LLP**
- Source: MarketBeat | 20251207T050325 | Somewhat-Bullish | Relevance: 97%
-  Marshall Wace LLP significantly increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 29.8% in Q2, now owning 276,480 shares valued at approximately $79.45 million. Despite recent insider selling, institutional ownership remains high, and analysts maintain a "Moderate Buy" rating with an average price target of $505.00. The biotechnology company reported strong Q3 earnings, surpassing consensus estimates, and continues to develop products addressing chronic and life-threatening diseases.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 15 ($11.95M) |
| Sells | 71 ($40.48M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Heavy insider selling: $40M sold (71 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 16.8x stretched relative to 5% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Insider selling cluster ($40.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.7B |
| Beta | 0.86 |
| 52W Range | $266.98 - $492.62 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 16.8 |
| Current P/E | 17.7 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.5% to -1.6% (+1.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.6pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.08), momentum weakening. RSI neutral at 58.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.57% (CS: 39) | Neutral |
| RSI_14 | 58.5 | Neutral |
| MACD Histogram | -1.08 | Bearish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 1.059x | Above |
| vs SMA200 | 1.369x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $479.51
- **Stop Loss:** $455.97 (4.9% risk)
- **Target:** $503.05 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 21
- **Position Value:** $10,069.71
- **Portfolio %:** 10.07%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*